:format(webp)/cdn.mskdoctors.com/storage/2026/5/PkceL2jRm6AEpsGwqStgtOY5GBKWnFaq.jpg)
BMAC or exosomes for knee osteoarthritisBMAC currently has the firmer clinical footing for knee osteoarthritis: a meta-analysis of 27 Level I studies showed BMAC and PRP both outperformed hyaluronic acid, but BMAC was not significantly better than PRP, and improvement is largely about pain and function rather than proven cartilage repair. Kellgren-Lawrence grade 2 knees…BMAC currently has the firmer clinical footing for knee osteoarthritis: a meta-analysis of 27 Level I studies showed BMAC and PRP both outperformed hyaluronic acid, but BMAC was not significantly better than PRP, and improvement is largely about pain and function rather than proven cartilage repair. Kellgren-Lawrence grade 2 knees respond better than more advanced disease, but harvest sites, processing and injection protocols still vary widely between studies. Exosomes have no FDA-approved produ...
:format(webp)/cdn.mskdoctors.com/storage/2026/5/abV3BrK73uU8EhUXEgihyuUTER4ZQ1Ug.jpg)
BMAC or exosomes for knee osteoarthritisThe article compares the evidence for BMAC and exosome injections in knee osteoarthritis, explaining that BMAC has stronger support for short-term pain and function improvement, especially in earlier disease, while exosomes remain experimental and unapproved. It also sets out what to ask clinics about preparation, suitability, safety and follow-up.The article compares the evidence for BMAC and exosome injections in knee osteoarthritis, explaining that BMAC has stronger support for short-term pain and function improvement, especially in earlier disease, while exosomes remain experimental and unapproved. It also sets out what to ask clinics about preparation, suitability, safety and follow-up.
